Alder BioPharmaceuticals (ALDR) Trading 17.4% Higher Following Analyst Upgrade

Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR)’s share price traded up 17.4% during trading on Tuesday after BMO Capital Markets raised their price target on the stock to $26.00. BMO Capital Markets currently has an outperform rating on the stock. Alder BioPharmaceuticals traded as high as $16.00 and last traded at $15.20. 6,900,700 shares traded hands during mid-day trading, an increase of 195% from the average session volume of 2,342,060 shares. The stock had previously closed at $12.95.

A number of other equities analysts have also commented on ALDR. Cowen assumed coverage on Alder BioPharmaceuticals in a report on Tuesday, September 26th. They issued an “outperform” rating and a $20.00 price target for the company. BidaskClub raised Alder BioPharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, January 4th. Mizuho reaffirmed a “buy” rating and issued a $29.00 price target (down from $32.00) on shares of Alder BioPharmaceuticals in a report on Tuesday. ValuEngine raised Alder BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, January 4th. Finally, Canaccord Genuity assumed coverage on Alder BioPharmaceuticals in a report on Thursday, October 26th. They issued a “buy” rating and a $20.00 price target for the company. Two research analysts have rated the stock with a sell rating, three have given a hold rating and eleven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $27.79.

In related news, insider Mark James Litton sold 16,519 shares of the stock in a transaction on Monday, November 13th. The stock was sold at an average price of $10.80, for a total value of $178,405.20. Following the sale, the insider now owns 116,451 shares in the company, valued at $1,257,670.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 10.60% of the company’s stock.

Several hedge funds have recently modified their holdings of ALDR. Russell Investments Group Ltd. raised its position in shares of Alder BioPharmaceuticals by 7.2% in the second quarter. Russell Investments Group Ltd. now owns 42,416 shares of the biopharmaceutical company’s stock worth $486,000 after buying an additional 2,837 shares in the last quarter. Rhumbline Advisers raised its position in shares of Alder BioPharmaceuticals by 8.5% in the second quarter. Rhumbline Advisers now owns 61,416 shares of the biopharmaceutical company’s stock worth $703,000 after buying an additional 4,825 shares in the last quarter. State of Wisconsin Investment Board purchased a new stake in shares of Alder BioPharmaceuticals in the second quarter worth $401,000. SG Americas Securities LLC raised its position in shares of Alder BioPharmaceuticals by 109.4% in the second quarter. SG Americas Securities LLC now owns 15,580 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 8,140 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its position in shares of Alder BioPharmaceuticals by 10.4% in the second quarter. Bank of New York Mellon Corp now owns 232,287 shares of the biopharmaceutical company’s stock worth $2,659,000 after buying an additional 21,886 shares in the last quarter. Institutional investors own 96.80% of the company’s stock.

The firm has a market capitalization of $1,170.00, a PE ratio of -3.23 and a beta of 2.48.

Alder BioPharmaceuticals (NASDAQ:ALDR) last issued its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.21) by $0.29. During the same period in the previous year, the company posted ($0.70) earnings per share. analysts anticipate that Alder BioPharmaceuticals, Inc. will post -5.14 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Alder BioPharmaceuticals (ALDR) Trading 17.4% Higher Following Analyst Upgrade” was posted by Markets Daily and is owned by of Markets Daily. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2018/01/11/alder-biopharmaceuticals-aldr-trading-17-4-higher-following-analyst-upgrade.html.

Alder BioPharmaceuticals Company Profile

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply